Newly Approved Cardiology Drugs (2022–2026)

Newly Approved Cardiology Drugs (2022–2026): The New Era of Precision Cardiovascular Medicine

The field of cardiovascular medicine is undergoing one of its most exciting transformations in decades. Rather than relying solely on traditional therapies, clinicians now have access to highly targeted drugs that address the underlying mechanisms of disease. Between 2022 and 2026, several breakthrough medications have either gained regulatory approval or reached major milestones, offering new hope for patients with hypertrophic cardiomyopathy, dyslipidemia, hypertriglyceridemia, resistant hypertension, obesity, and arrhythmias.

This article reviews these landmark therapies, their mechanisms of action, clinical indications, key trials, and future role in cardiovascular practice.

---

Timeline of Recent Cardiovascular Drug Innovations

• 2022 – Mavacamten

• 2023 – Aficamten

• 2024 – Semaglutide (Cardiovascular Risk Reduction)

• 2025 – Etripamil

• 2025 – Lerodalcibep

• 2025 – Plozasiran

• 2026 – Olezarsen

• 2026 – Enlicitide

• 2026 – Baxdrostat

---

1. Mavacamten (2022)

Drug Class

Selective cardiac myosin inhibitor

Mechanism of Action

Mavacamten reduces excessive actin-myosin cross-bridge formation, decreasing myocardial hypercontractility and improving diastolic relaxation.

Unlike conventional drugs that mainly reduce heart rate or blood pressure, Mavacamten directly targets the underlying pathophysiology of hypertrophic cardiomyopathy.

Approved Indication

Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Clinical Benefits

• Reduces LVOT gradient

• Improves NYHA functional class

• Increases exercise capacity

• Improves quality of life

• May delay septal reduction therapy

Landmark Trials

• EXPLORER-HCM

• VALOR-HCM

Important Monitoring

• Echocardiography every 8–12 weeks during dose titration

• Monitor LVEF

• Avoid excessive reduction in systolic function

Clinical Pearl

The first disease-specific therapy that targets the molecular mechanism of hypertrophic cardiomyopathy.

---

2. Aficamten (2023)

Drug Class

Second-generation cardiac myosin inhibitor

Why It Is Different

Although similar to Mavacamten, Aficamten has:

• Shorter half-life

• Faster onset and offset

• Easier dose titration

• Reduced risk of prolonged myocardial depression

Potential Advantages

Better dosing flexibility

Simpler monitoring

Rapid adjustment when EF falls

Landmark Trial

SEQUOIA-HCM

Future Role

Expected to become another important treatment option for obstructive HCM with potentially easier clinical management.

---

3. Semaglutide (2024)

Drug Class

GLP-1 receptor agonist

Cardiovascular Importance

Initially developed for diabetes, Semaglutide has become a major cardiovascular drug after demonstrating significant reduction in major adverse cardiovascular events.

Mechanism

• Weight reduction

• Improved insulin sensitivity

• Reduced inflammation

• Better endothelial function

• Blood pressure reduction

Cardiovascular Benefits

• Reduced cardiovascular death

• Lower risk of myocardial infarction

• Reduced stroke

• Significant weight loss

Landmark Trial

SELECT Trial

The SELECT trial demonstrated cardiovascular benefit even in overweight or obese patients without diabetes but with established cardiovascular disease.

---

4. Etripamil (2025)

Drug Class

Intranasal calcium channel blocker

Mechanism

Rapid nasal absorption produces AV nodal blockade and can terminate AV node-dependent supraventricular tachycardia.

Clinical Use

Self-administered treatment of:

• Paroxysmal supraventricular tachycardia (PSVT)

Advantages

No IV line required

Rapid onset

Patient-controlled therapy

Potential reduction in emergency department visits

Why It Matters

For the first time, many patients with recurrent SVT may be able to terminate episodes themselves outside the hospital.

---

5. Lerodalcibep (2025)

Drug Class

Long-acting PCSK9 inhibitor

Mechanism

Inhibits PCSK9, increasing LDL receptor recycling and enhancing LDL cholesterol clearance.

Benefits

Marked LDL reduction

Less frequent dosing

Improved patient adherence

Potential alternative to currently available injectable PCSK9 inhibitors

Potential Candidates

Familial hypercholesterolemia

Very high cardiovascular risk

Statin intolerance

Persistent LDL elevation despite maximal therapy

---

6. Plozasiran (2025)

Drug Class

APOC3 siRNA therapy

Mechanism

Silences APOC3 gene expression.

Reduced ApoC-III increases triglyceride clearance.

Clinical Benefits

Major reduction in triglycerides

Reduction in chylomicrons

Improved metabolic profile

Target Population

Familial chylomicronemia syndrome

Severe hypertriglyceridemia

Patients at risk of pancreatitis

---

7. Olezarsen (2026)

Drug Class

APOC3 antisense oligonucleotide

Mechanism

Blocks production of ApoC-III protein.

Benefits

Marked triglyceride reduction

Reduced pancreatitis risk

Improved lipid metabolism

Clinical Importance

Represents another precision medicine approach for patients with genetically mediated severe hypertriglyceridemia.

---

8. Enlicitide (2026)

Drug Class

Oral PCSK9 inhibitor

Why It Is Revolutionary

Until now, PCSK9 inhibitors required injections.

Enlicitide introduces oral LDL-lowering therapy targeting the same pathway.

Potential Advantages

Improved patient acceptance

Better adherence

Reduced need for injections

Expansion of intensive lipid-lowering therapy

Likely Candidates

Very high-risk ASCVD

Familial hypercholesterolemia

Statin intolerance

Persistent LDL elevation

---

9. Baxdrostat (2026)

Drug Class

Selective aldosterone synthase inhibitor

Mechanism

Reduces aldosterone production by selectively inhibiting CYP11B2.

Unlike mineralocorticoid receptor antagonists, it decreases aldosterone synthesis rather than blocking its receptor.

Potential Benefits

Lower blood pressure

Reduced aldosterone-mediated fibrosis

Reduced cardiac remodeling

Renal protection

Primary Indication

Resistant hypertension

Landmark Trial

BrigHTN Trial

---

Emerging Themes in Modern Cardiology

These therapies highlight several important trends:

• Precision medicine targeting disease mechanisms rather than symptoms.

• Gene-silencing technologies (siRNA and antisense oligonucleotides) for lipid disorders.

• Oral alternatives replacing injectable biologics.

• Home-based therapies such as intranasal Etripamil for selected arrhythmias.

• Disease-modifying treatments for cardiomyopathies.

• Expanded use of metabolic therapies for cardiovascular risk reduction.

---

Which Specialists Will Use These Drugs?

• Cardiologists

• Electrophysiologists

• Heart failure specialists

• Lipidologists

• Hypertension specialists

• Endocrinologists

• Internal medicine physicians

---

Key Take-Home Messages

• Mavacamten introduced targeted therapy for obstructive hypertrophic cardiomyopathy.

• Aficamten offers a next-generation myosin inhibitor with easier titration.

• Semaglutide has expanded from diabetes treatment to cardiovascular risk reduction.

• Etripamil may allow patients with PSVT to self-treat episodes outside the hospital.

• Lerodalcibep and Enlicitide represent the next evolution in LDL-cholesterol lowering.

• Plozasiran and Olezarsen use RNA-based technology to dramatically reduce triglycerides in severe hypertriglyceridemia.

• Baxdrostat introduces a novel approach to resistant hypertension by selectively inhibiting aldosterone synthesis.

---

Conclusion

The years 2022–2026 have marked a pivotal shift toward mechanism-based cardiovascular therapeutics. These agents extend beyond symptom control by targeting molecular pathways responsible for hypertrophic cardiomyopathy, dyslipidemia, obesity, hypertriglyceridemia, arrhythmias, and resistant hypertension. As evidence continues to evolve, these therapies are poised to reshape clinical practice and improve long-term cardiovascular outcomes through more personalized and effective treatment strategies.

For more cardiology articles and professional infographics, visit: drmusmanjaved.com